Zofia Czaplińska-Paszek

Zofia Czaplińska-Paszek

Auto-generated profile, based on publicly available information

Zofia Czaplińska-Paszek

Medical University of Warsaw, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in Lekarz Wojskowy
Verified
Journal Article
Open access
PDF file
SPSławomir Piotr Paszek
Sławomir Piotr Paszek
MRMarcin Rabijewski
Marcin Rabijewski
AKAnna Kurek
Anna Kurek
HGHubert Goetz
Hubert Goetz
ZCZofia Czaplińska-Paszek
Zofia Czaplińska-Paszek
Wprowadzenie i cel: Obecna sytuacja geopolityczna oraz trwające konflikty zbrojne o zasięgu międzynarodowym skłaniają do refleksji na temat poziomu przygotowania kadr medycznych na wypadek konieczności ich udziału w realnym konflikcie zbrojnym. Z tego powodu autorzy postanowili poddać ocenie kompetencje lekarzy stażystów, a więc osób rozpoczynających karierę zawodową, realizujących aktualny program nauczania. Materiał i metody: Opracowano autorski formularz składający się z 10 zamkniętych pytań jednokrotnego wyboru, mający ocenić znajomość procedur opracowanych przez Komitet Tactical Combat Casualty Care (TCCC). Wyniki: Średni wynik uzyskany przez lekarzy stażystów wyniósł niespełna 30% poprawnych odpowiedzi. Dodatkowo udało się ustalić obszary, które stanowią największą trudność dla respondentów, takie jak antybiotykoterapia czy tamowanie krwotoków. Wnioski: Uzyskane wyniki wskazują na potrzebę rozważenia rozszerzenia programu nauczania na kierunku lekarskim o treści obejmujące zagadnienia z zakresu TCCC, a także wykorzystania zagranicznych doświadczeń w celu rozwijania współpracy szkoleniowej o zasięgu międzynarodowym.

2 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
MBMichał Borowski
Michał Borowski
KPKinga Popielarska
Kinga Popielarska
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.

2 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
MBMichał Borowski
Michał Borowski
KPKinga Popielarska
Kinga Popielarska
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.

3 January 2026 in Quality in Sport
Verified
Journal Article
Open access
JMJulia Agnieszka Michalak
Julia Agnieszka Michalak
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
KPKinga Popielarska
Kinga Popielarska
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.

1 January 2026 in Safety and Fire Technology
Verified
Journal Article
Open access
SPSławomir Paszek
Sławomir Paszek
ZCZofia Czaplińska-Paszek
Zofia Czaplińska-Paszek
Purpose: The aim of this study was to assess the frequency of Kendrick extrication device (KED) use among rescuers and to analyse the current scientific evidence regarding its effectiveness and safety. The study was motivated by differences observed in recent years in the qualified first aid training programmes for State Fire Service (PSP) and Volunteer Fire Service (OSP) firefighters with regard to the use of this device Project and methods: The study was conducted between July 2022 and March 2026 among 210 firefighters, using a diagnostic survey with an original questionnaire distributed via Google Forms. The survey was addressed to firefighters serving in both professional and volunteer fire protection units. The questionnaire was disseminated through social media platforms and professional groups bringing together individuals involved in fire protection services. Responses concerning the frequency of Kendrick Extrication Device use, equipment availability, and subjective assessment of its usefulness in rescue operations were analysed. In addition, a review of the current scientific literature on the effectiveness, safety, and potential complications of the Kendrick extrication device in prehospital medicine was conducted using publications available in PubMed, Scopus, and Google Scholar. Results: More than half of the surveyed rescuers reported not having used the Kendrick Extrication Device in practice while providing qualified first aid. A substantial proportion of respondents also indicated that this device was not available in the equipment of their rescue units. The most frequently reported reason for the device's limited use was the time required to apply it properly during patient extrication. Analysis of the available literature suggests that the use of spinal immobilisation devices in selected situations may be associated with a risk of complications and prolonged patient extrication time. Conclusions: The study findings indicate limited use of the Kendrick extrication device in rescue practice and low availability of this equipment in State Fire Service units. Respondents identified the time-consuming nature of device application during patient extrication as the main reason for abandoning its use. Current scientific evidence suggests that rapid patient extrication without this type of equipment may be a safe alternative in selected clinical situations. The results obtained may support the rationale for limiting the use of the Kendrick Extrication Device and highlight the need for further research into more intuitive and effective methods for patient extrication and stabilization.

6 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZCZofia Czaplińska-Paszek
Zofia Czaplińska-Paszek
KRKornelia Rynkiewicz
Kornelia Rynkiewicz
NBNatalia Bogusz
Natalia Bogusz
SPSławomir Paszek
Sławomir Paszek
Introduction and objective: Sudden cardiac arrest (SCA) during outdoor sport training is a complication where a quick response from medical professionals is crucial for increasing chances of survival. In parallel with the global growth in running events, there is a need to implement new recommendations and technologies to improve prevention, detection, and treatment of SCA among runners. Review Methods: A comprehensive literature review was conducted, analyzing studies indexed in PubMed, Google Scholar, and the official ERC Guidelines from 2021 and 2025. Key findings: Recent data suggest that, although the number of SCA cases in mass running events has remained relatively stable over the past decade, running-related deaths have declined. These outcomes are likely attributable to significant improvements in emergency action planning, widespread AED availability, and enhanced first-aid education. There are also new ideas that can further improve those outcomes, not only in treatment but also in SCA prophylaxis. New preventive and diagnostic strategies, such as point-of-care blood gas analysis (POC BGA) and risk-profiling patient triage, focus primarily on early triage and smartwatch pulse-detector systems, offering a new perspective on more rapid detection of SCA during outdoor activity. Advances in treatment focus on optimizing the prehospital chain of survival through mobile AED teams, GPS-enabled responder coordination, and structured “field-of-play” protocols. Further research is needed to reduce the time to defibrillation and improve neurological outcomes during endurance events.